Evidence map›Paper›PMID 23578791›Full record

ReviewJournal of the neurological sciences2013

Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination.

Abdolmohamad Rostami, Bogoljub Ciric

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Journal of the neurological sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04674163 (NEUROKINASE), which is not on this map. Cited by 144 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04674163 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

NEUROKINASE : Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.

TypeinterventionalSponsorCentre Hospitalier Régional d'OrléansRan2023 to 2023Enrolled0ConditionsSclerosis, Multiple, Guillain-Barre Syndrome, InflammationArmsBlood sample and Cerebrospinal fluid (CSF) collection.
3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 1 synthesis or guideline pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Extracellular vesicle-based therapies for neurodegenerative diseases.NeuroImmune pharmacology and therapeutics · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Abdolmohamad RostamiDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA. Electronic address: A.M.Rostami@jefferson.edu.
Bogoljub Ciric
Thomas Jefferson University · US

Funding

The Role of the TH17 cells in the pathogenesis of EAER01NS046782 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI ROSTAMI, A.M. · 2003 to 2013
$2.7M
NINDS NIH HHS 5R01NS046782NINDS NIH HHS R01 NS046782PHS HHS 1U19A1082726
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). The etiology of MS is not well understood, but it is believed that myelin-specific CD4(+) T cells play a central role in initiating and orchestrating CNS inflammation. In this scenario, CD4(+) T cells, activated in the periphery, infiltrate the CNS, where, by secreting cytokines and chemokines, they start an inflammatory cascade. Given the central role of CD4(+) T cells in CNS autoimmunity, they have been studied extensively, principally by using experimental autoimmune encephalomyelitis (EAE), an animal model of MS. In the late 1980s, CD4(+) T cells, based on their cytokine production, were divided into two helper lineages, Th1 and Th2 cells. It was postulated that Th1 cells, which produce IFN-γ, mediate inflammation of the CNS in MS/EAE, while Th2 cells, which produce IL-4, have a beneficial effect in disease, because of their antagonistic effect on Th1 cells. The Th1/Th2 paradigm remained the prevailing view of MS/EAE pathogenesis until 2005, when a new lineage, Th17, was discovered. In a relatively short period of time it became apparent that Th17 cells, named after their hallmark cytokine, IL-17A, play a crucial role in many inflammatory diseases, including EAE, and likely in MS as well. The Th17 paradigm developed rapidly, initiating the debate of whether Th1 cells contribute to EAE/MS pathogenesis at all, or if they might even have a protective role due to their antagonistic effects on Th17 cells. Numerous findings support the view that Th17 cells play an essential role in autoimmune CNS inflammation, perhaps mainly in the initial phases of disease. Th1 cells likely contribute to pathogenesis, with their role possibly more pronounced later in disease. Hence, the current view on the role of Th cells in MS/EAE pathogenesis can be called the Th17/Th1 paradigm. It is certain that Th17 cells will continue to be the focus of intense investigation aimed at elucidating the pathogenesis of CNS autoimmunity.

Indexed as

AnimalsAutoimmunityCD4-Positive T-LymphocytesCentral Nervous SystemCytokinesDemyelinating DiseasesEncephalomyelitis, Autoimmune, ExperimentalHumansInflammationMultiple SclerosisTh17 CellsTh1 CellsTh2 CellsCytokinesantigen presenting cellsAPCcentral nervous systemCNSEAEexperimental allergic encephalomyelitisGM-CSFgranulocyte macrophage colony-stimulating factorIFNILIL-23IL-27interferoninterleukinMBPMOGMSmultiple sclerosisMultiple sclerosismyelin basic proteinmyelin oligodendrocyte glycoproteinnitric oxideNOregulatory T cellsTh1Th17Th9TNFTregTregstumor necrosis factorwild-typeWTγδ T cell

Identifiers

PMID23578791
PMCPMC3726569
OpenAlexW2139321499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.